CORRECTIONS

Author Correction

The June 20, 2011, article by Yang et al, entitled “*SLCO2B1* and *SLCO1B3* May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer” (J Clin Oncol 29:2565-2573, 2011), contained errors.

In the Results section, under “Association of *SLCO2B1* SNPs With TTP During ADT,” rs12422149A>G was given in the second sentence, whereas it should have been rs12422149G>A, as follows: “Three polymorphisms of *SLCO2B1*, **rs12422149G>A** (Arg312Gln) in exon 7, rs1789693A>T in intron 7 and rs1077858A>G in intron 8, were significantly associated with TTP during ADT in univariate analysis ($P = .029, .007$, and $.009$, respectively).”

In the Results section, under “Differential DHEAS Uptake of *SLCO2B1* Variants,” rs12422149A>G was given in the first paragraph, whereas it should have been rs12422149G>A, as follows: “To address the biologic function of different *SLCO2B1* variants responding to ADT, we investigated the possibility that the *SLCO2B1* **rs12422149G>A** (Arg312Gln) SNP may influence the efficiency of DHEAS transport, thus affecting intracellular levels of androgen and cellular responses to ADT. We chose the *SLCO2B1* **rs12422149G>A** (Arg312Gln) SNP for functional analysis, because it is an exonic SNP, resulting in an amino acid change.”

In the Results section, under the same subsection, *SLCO2B1*-312Gln and *SLCO2B1*-312Arg should have been transposed in the last sentence of the second paragraph and throughout the third paragraph, as follows: “The ***SLCO2B1*-312Arg** expressor exhibited a maximal uptake of 223.38 ± 8.55 pmol/mg protein, the ***SLCO2B1*-312Gln** expressor exhibited a maximal uptake of 162.76 ± 25.73 pmol/mg protein, and the pCMV6-XL4 vector mock-transfected cells exhibited an uptake of 51.66 ± 7.44 pmol/mg protein. “. . . The best-fit K_m values for the ***SLCO2B1*-312Arg** and ***SLCO2B1*-312Gln** variants were $17.65 \mu\text{mol/L}$ (95% CI, 9.303 to $25.99 \mu\text{mol/L}$) and $13.68 \mu\text{mol/L}$ (95% CI, 4.174 to $23.20 \mu\text{mol/L}$), respectively. The maximum velocity values for the **312Arg** and **312Gln** variants were 281.4 pmol/mg protein/min (95% CI, 236.1 to 326.7 pmol/mg protein/min) and 189.5 pmol/mg protein/min (95% CI, 147.8 to 231.2 pmol/mg protein/min). These results indicate that both *SLCO2B1* variants can import DHEAS, although the ***SLCO2B1*-312Arg** variant exhibits a greater efficiency. We hypothesized that the higher efficiency of the ***SLCO2B1*-312Arg** variant in transporting DHEAS into CaP cells leads to a greater ability to activate AR, which may in turn sustain cell growth, thereby explaining why patients with the ***SLCO2B1*-312Arg** variant exhibited a shorter TTP during ADT.”

In the Results section, under “Impact of DHEAS Import on AR Signaling and Cell Growth,” *SLCO2B1*-312Gln and *SLCO2B1*-312Arg should have been transposed in the third, fourth, and sixth sentences of the first paragraph, as follows: “While both LNCaP and

LAPC-4 transfected with the ***SLCO2B1*-312Arg** variant showed consistently higher PSA expression levels than those of cells transfected with the ***SLCO2B1*-312Gln** variant (Figs 3A and 3B); this correlation was only statistically significant in LAPC-4 (Fig 3B). Specifically, treatment with $100 \mu\text{mol/L}$ DHEAS upregulated the PSA expression in LAPC-4 harboring the ***SLCO2B1*-312Arg** variant by 1.48-fold, compared to that in cells with the ***SLCO2B1*-312Gln** variant. . . . Cells carrying the ***SLCO2B1*-312Arg** variant and treated with $100 \mu\text{mol/L}$ DHEAS exhibited a 1.24-fold higher level of AR expression than that in cells with the ***SLCO2B1*-312Gln** variant.”

In the Results section, under the same subsection, *SLCO2B1*-312Gln and *SLCO2B1*-312Arg should have been transposed in the fourth sentence of the second paragraph, as follows: “In the presence of DHEAS, the growth efficiency of LNCaP transfected with ***SLCO2B1*-312Arg** increased 2.5-fold, while the growth efficiency of LNCaP cells transfected with ***SLCO2B1*-312Gln** only increased 2.0 fold ($P < .05$).”

In the Discussion section, rs12422149A>G was given in the fourth sentence of the first paragraph, whereas it should have been rs12422149G>A, as follows: “Three *SLCO2B1* SNPs, **rs12422149G>A**, rs1789693A>T and rs1077858A>G were associated with TTP on ADT.”

In the Discussion section, *SLCO2B1*-312Gln and *SLCO2B1*-312Arg should have been transposed in the first sentence of the fourth paragraph, as follows: “We found that when treated with DHEAS, cells transfected with ***SLCO2B1*-312Arg** consistently exhibited higher PSA levels than those transfected with ***SLCO2B1*-312Gln**, although the significant differences were only observed in LAPC-4 cells.”

In Figure 2B and all parts of Figure 3, the labels for *SLCO2B1*-312Gln and *SLCO2B1*-312Arg should have been transposed.

In the Data Supplement, under “Plasmids, Cell Culture and Transfections,” 935G, encoding 312Gln was given in the first sentence of the first paragraph, whereas it should have been 935G, encoding 312Arg. In the second sentence of the paragraph, pCMV-*SLCO*-312Gln and pCMV-*SLCO*-312Arg should have been transposed. The corrected text is as follows: “The *SLCO2B1* 935G>A nucleotide exchange was introduced into the pCMV6-XL4-*SLCO2B1* plasmid (935G, encoding **312Arg**; OriGene, Rockville, MD) using the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). The original and the mutagenized constructs were designated as pCMV-*SLCO*-**312Arg** and pCMV-*SLCO*-**312Gln**, respectively.”

The online version has been corrected in departure from the print. The authors apologize for the mistakes.

DOI: 10.1200/JCO.2012.44.8084; published July 10, 2012